GCM
CAI

Ghisallo Capital Management’s Caris Life Sciences CAI Stock Holding History

Ghisallo Capital Management’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.47M Sell
250,000
-595,332
-70% -$13M 0.12% 132
2025
Q4 		$22.8M Sell
845,332
-202,831
-19% -$5.71M 1.02% 20
2025
Q3 		$31.7M Hold
1,048,163
– – 1.04% 21
2025
Q2 		$28M Buy
+1,048,163
New +$28.2M 0.75% 31

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $326M AUM
SSP
Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Ghisallo Capital Management's CAI Position: Q1 2026 in Review

Ghisallo Capital Management reduced its Caris Life Sciences (CAI) stake by 70% in Q1 2026, selling an estimated $13M and leaving 250,000 shares worth $4.47M. The position accounts for 0.12% of the portfolio, ranked #132.

Ghisallo Capital Management first reported a position in CAI in Q2 2025 and has held it in 4 quarters since. The position peaked at $31.7M in Q3 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Ghisallo Capital Management held 250,000 shares of Caris Life Sciences worth $4.47M as of Q1 2026.
  • Ghisallo Capital Management sold 595,332 Caris Life Sciences shares in Q1 2026, an estimated $13M.
  • Caris Life Sciences made up 0.12% of Ghisallo Capital Management's portfolio in Q1 2026, its #132 holding.
  • Ghisallo Capital Management first reported a position in Caris Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • Ghisallo Capital Management's Caris Life Sciences position peaked at $31.7M in Q3 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Ghisallo Capital Management's 13F filing for Q1 2026, filed 15 May 2026.